tiprankstipranks
Matinas BioPharma Slashes Workforce Amid Financial Turmoil
Company Announcements

Matinas BioPharma Slashes Workforce Amid Financial Turmoil

Pick the best stocks and maximize your portfolio:

Matinas BioPharma ( (MTNB) ) has issued an update.

Matinas BioPharma Holdings has announced an 80% workforce reduction and halted its product development activities as a strategic move to conserve cash following the termination of partnership negotiations for its MAT2203 product. The company is considering options such as a potential asset sale or even dissolving the company itself. This drastic measure comes as Matinas seeks to navigate significant financial challenges and uncertainties in the biotech industry.

For detailed information about MTNB stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMatinas BioPharma Faces Uncertain Future After Halting MAT2203 Development
Howard KimIs MTNB a Buy, Before Earnings?
TheFlyMatinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App